14
panel
FasterCures Board Retreat (Invite only)
FasterCures' Advisory Board is comprised of eminent medical researchers and industry executives
who will help inform the center's work going forward.
+ Read More
panel
FasterCures Nonprofit Council Meeting (Invite only)
Members of the FasterCures Nonprofit Council are recognized global leaders in biomedical innovat
ion and lead high-profile, not-for-profit organizations dedicated to accelerating treatments to patients globally.
+ Read More
panel
FasterCures Private Dinner (Invite only)
panel
FasterCures Private Dinner (Invite only)
panel
An Intimate Gathering of Global Health Leaders (Invite only)
On behalf of FasterCures Advisory Board member Dr. Annalisa Jenkins and Sir Michael Hintze, we w
ould like to invite you to join us for a private reception at the Beverly Wilshire.
+ Read More
video
A Conversation with FDA Commissioner Stephen Hahn
Esther Krofah, Executive Director of FasterCures, hosts FDA Commissioner Stephen Hahn as part
of Summer Series 2020.
+ Read More
video
Venture Philanthropy in Action: A Case Study of EB Research Partnership and ProQR
How are nonprofit organizations leveraging venture philanthropy to accelerate the development of t
reatments and cures?
+ Read More
video
The Global Mental Health Pandemic
Mental health and substance abuse have been identified as the leading cause of disability worldwid
e.
+ Read More
video
Can the World's Biggest Companies Save Health Care?
For a number of years now, the dominant technology platforms such as Google and Amazon have been f
lirting with how they might be able to disrupt the health-care industry, a critical and growing economic driver badly in need of new ideas and more data-dr
+ Read More
video
In Search for a Cure: Are We Nearing a Treatment for COVID-19?
Since starting its rapid global spread in early 2020, COVID-19 has put conventional methods of res
earch and development to the test.
+ Read More
video
Getting More From Biomedical Innovation
In 2018 the FDA approved a record number of new products, but pharmaceutical R&D returns have
fallen to their lowest level in nine years.
+ Read More